Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, the immunohistochemistry and qPCR results reported in our study suggested the idea that USP28 in coordination with p53 could serve as a marker in BCa progression.
|
31822365 |
2020 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that upregulated HIF1A-AS2 hampers the p53 family proteins dependent apoptotic pathway to promote Cis resistance in bladder cancer.
|
30216500 |
2019 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GTSE1 overexpression in bladder cancer might participate in the regulation of FoxM1/CCNB1 expression via the induction of the transfer of p53 to cytoplasm.
|
30414902 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.
|
30650148 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
GADD45a Mediated Cell Cycle Inhibition Is Regulated By P53 In Bladder Cancer.
|
31571910 |
2019 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor cells of luminal, basal, and p53 subtypes of primary and relapsed NMIBC were engrafted to irradiated (3.5 Gy) NOG/SCID female mice along with intraperitoneal transplantation of human lymphocytes (5 × 10<sup>7</sup> cells/mouse); a role of PD-L1 signaling pathway inhibition for bladder cancer growth was assessed in humanized animals that carried PD-L1-expressing main molecular subtypes of bladder carcinoma patient-derived xenografts (PDX) and provided with selective anti-PD-L1 treatment.
|
31159302 |
2019 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BBN-induced tumors in mice recapitulate the histology of human BC and were characterized with an overexpression of markers typical for basal-like cancer subtype in addition to a high mutational burden with frequent mutations in Trp53, similar to human muscle invasive BC.
|
31779626 |
2019 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to elucidate the association between TP53 codon 72 polymorphism and somatic mutations in bladder cancer.
|
31369573 |
2019 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the prognostic value of tumor-associated trypsin inhibitor (TATI) expression combined with p53 expression in bladder cancer patients who have undergone radical cystectomy.
|
31594208 |
2019 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Intrinsic and/or acquired resistance to cisplatin is a significant obstacle in the treatment of muscle-invasive bladder cancer. p73, a p53 homolog and determinant of chemosensitivity, is rarely mutated in bladder cancer (BC).
|
31318640 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bladder cancer (BC) ranks as the sixth most common cancer in the United States and is the leading cause of death in patients with urinary malignancies. p63 is a member of the p53 family and is believed to function as a tumor suppressor in human BCs.
|
30104251 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
High expression of both cytoplasmic DDX31 and p53 proteins correlated with poor prognosis in patients with MIBC, and blocking the DDX31/NCL interaction resulted in downregulation of EGFR/Akt signaling, eliciting an <i>in vivo</i> antitumor effect against bladder cancer.
|
29440146 |
2018 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the relationship between TP53 codon 72 polymorphisms and BC tumor stage in Asian group, positive results were presented in <i>allele model</i>: OR=1.68, 95% CI=1.04-2.72; <i>dominant model</i>: OR=2.46, 95% CI=1.08-5.61; <i>heterozygous model</i>: OR=2.32, 95% CI=1.04-5.14; <i>homozygote model</i>: OR=2.66, 95% CI=1.04-6.81.
|
30310509 |
2018 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, TPX2 overexpression promoted while overexpression of GLIPR1 or p53 inhibited bladder cancer growth.
|
28799673 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
|
28577130 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many malignancies display amplification of MDM genes encoding negative regulators of p53 and therefore much effort to date has concentrated on the development of molecules that inhibit MDM2, the most advanced of which are being tested in clinical trials for sarcoma, glioblastoma, bladder cancer and lung adenocarcinoma.
|
28927521 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In spite of extensive literature, little is known about the role of FOXO1 and its relationship with p53 status in bladder cancer.
|
28087474 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relevant articles improved the understanding on p53 pathways and their potential as candidate to targeted therapy in bladder cancer.
|
28281901 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients from four Northern German institutions with a primary diagnosis of pT1 bladder cancer between 2009 and 2016 and complete data regarding p53 or Ki-67 expression status were included for final analyses.
|
29354488 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phthalazino[1,2-b]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells.
|
28745887 |
2017 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both the ECV-304 and EJ cell lines, that probably originate from the bladder carcinoma T24 cell line, were confirmed to contain the homozygous 378C>G mutation but were shown to produce the p53 protein of expected full-length size detected by Western blotting.
|
28961258 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, in this study we investigated the cytotoxic and toxicogenetic activity of silibinin in bladder cancer cells with different TP53 statuses.
|
28229968 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated how Rb is integrated to control bladder cancer progression through E2F3 and p53 regulation.
|
27922689 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibitory member of the apoptosis-stimulating protein of p53 is overexpressed in bladder cancer and correlated to its progression.
|
28489738 |
2017 |